Commitment to Regulation
Ensuring Safety, Quality, and Global Compliance
At KeyZell Biotech, our commitment to regulatory excellence is unwavering. We understand that ensuring the safety, efficacy, and quality of our therapies is paramount. From developing our groundbreaking drug LZ-167 to advancing clinical trials, every step aligns with stringent international standards.
Our regulatory roadmap reflects our determination to bring innovative and reliable cancer treatments to market while building trust with patients, healthcare providers, and investors.
Our Regulatory Strategy
1. Adherence to International Standards
KeyZell actively works to meet and exceed the requirements of key regulatory bodies, including:
- European Medicines Agency (EMA) for certification within the European Union.
- U.S. Food and Drug Administration (FDA) for future approvals in North America.
- Regulatory agencies in Mexico (COFEPRIS), Australia TGA), and Thailand (FDA), aligning with our global market strategy.
2. CE Mark Certification
As part of our focus on compliance, KeyZell is in the process of obtaining the CE Mark, which is essential for marketing medical devices in the European Economic Area. This certification ensures:
- Conformance to health, safety, and environmental protection standards.
- Validation of our AI-driven platforms like O.P.S. and O.D.S., which support the development and application of LZ-167.
3. Preclinical and Clinical Validation
Our regulatory efforts extend to every phase of development, including:
- Preclinical Trials: Completed with a demonstrated 80% efficacy for LZ-167 across multiple cancer types.
- Ethical Approvals: Successfully secured for clinical trials in both Mexico and Australia.
- Clinical Trials: Preparing to launch multiple studies in 2025 targeting breast and lung cancer.
Global Collaborations and Compliance
KeyZell collaborates with leading healthcare institutions and research centers to ensure adherence to local and international regulatory frameworks:
Partnerships with hospitals
Such as the Hospital Universitario Virgen de Macarena, Hospital Universitario Príncipe de Asturias in Spain and leading oncology centers in Mexico.
Active engagement
With regulatory consultants to streamline approvals in diverse markets.
Transparency and Patient Safety
1. Data Integrity and Monitoring
We prioritize robust data collection and análisis, ensuring transparency and reproducibility of results:
• Comprehensive monitoring of clinical trial phases to address patient safety and efficacy.
• Collaboration with independent ethical committees to uphold rigorous standards.
2. Continuous Improvement
KeyZell Biotech employs a proactive approach to compliance, continuously refining processes to align with evolving regulatory landscapes.
3. Commitment to Patients
• Ensuring that LZ-167 reaches the market with the highest safety and quality standards.
• Leveraging AI to personalize treatment options and improve patient outcomes while adhering to global ethical guidelines.
Your Trust, Our Priority
Our commitment to regulation ensures that every innovation we deliver meets the highest standards of safety and effectiveness. Whether you are a patient advocate, healthcare provider, or investor, KeyZell welcomes your collaboration in bringing life-changing therapies to market.
